BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) and Coherus BioSciences Inc. (NASDAQ:CHRS) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals Inc.	20.65M	45.50	101.25M	-0.93	0.00
Coherus BioSciences Inc.	N/A	0.00	209.34M	-3.13	0.00

In table 1 we can see BioCryst Pharmaceuticals Inc. and Coherus BioSciences Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals Inc.	-490.31%	-141%	-58.5%
Coherus BioSciences Inc.	0.00%	-742.4%	-126.3%

Volatility and Risk

BioCryst Pharmaceuticals Inc. is 80.00% more volatile than Standard and Poor’s 500 due to its 1.8 beta. Coherus BioSciences Inc.’s 263.00% more volatile than Standard and Poor’s 500 which is a result of the 3.63 beta.

Liquidity

BioCryst Pharmaceuticals Inc.’s Current Ratio is 2 while its Quick Ratio is 2. On the competitive side is, Coherus BioSciences Inc. which has a 5.3 Current Ratio and a 5.3 Quick Ratio. Coherus BioSciences Inc. is better positioned to pay off short and long-term obligations compared to BioCryst Pharmaceuticals Inc.

Analyst Ratings

The table given features the ratings and recommendations for BioCryst Pharmaceuticals Inc. and Coherus BioSciences Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
BioCryst Pharmaceuticals Inc.	0	1	3	2.75
Coherus BioSciences Inc.	0	0	2	3.00

BioCryst Pharmaceuticals Inc.’s upside potential is 58.26% at a $13.5 consensus price target. On the other hand, Coherus BioSciences Inc.’s potential upside is 69.15% and its consensus price target is $25. Based on the analysts view we can conclude, Coherus BioSciences Inc. is looking more favorable than BioCryst Pharmaceuticals Inc.

Institutional and Insider Ownership

Roughly 94% of BioCryst Pharmaceuticals Inc. shares are owned by institutional investors while 98.8% of Coherus BioSciences Inc. are owned by institutional investors. Insiders owned roughly 1% of BioCryst Pharmaceuticals Inc.’s shares. On the other hand, insiders owned about 0.4% of Coherus BioSciences Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
BioCryst Pharmaceuticals Inc.	3.17%	1.27%	-8.44%	20.91%	79.02%	8.92%
Coherus BioSciences Inc.	1.49%	11.66%	36.64%	-25.41%	53.37%	66.08%

For the past year BioCryst Pharmaceuticals Inc. has weaker performance than Coherus BioSciences Inc.

Summary

On 6 of the 11 factors BioCryst Pharmaceuticals Inc. beats Coherus BioSciences Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.